National Surveillance of Nosocomial Septicemia (Hospital-wide)

Size: px
Start display at page:

Download "National Surveillance of Nosocomial Septicemia (Hospital-wide)"

Transcription

1 National Surveillance of Hospital Infections National Surveillance of Nosocomial Septicemia (Hospital-wide) National analysis Data from 01/01/2008 to 31/12/2008

2 1. SUMMARY BY QUARTER Quarter Patient records SEP records MO records N of admissions from to 2008q1 01/01/ /04/ d d q2 01/04/ /07/ d d q3 01/07/ /11/ d d q4 01/10/ /01/ d d Patient-days Length of stay N admissions in intensive care Pt-days IC LOS IC N hemoc. N hc/1000 ptd N SEP>D2 % N SEP>D2 icu % TOTAL 01/01/ /01/ d d Page 2 Summary

3 2. Data quality check Total number of surveillance quarters 199 Whocare 0 NSIHwin 199 a. Denominator data a.1. Standard denominator data Complete records 144 Missing n of hospital admissions 0 Missing n of patient-days 0 Missing n of ICU admissions 53 Missing n of ICU patient-days 52 Missing n of hemocultures 2 a.2. Optional data (quality decree Fl. Comm.)* >=1 optional variable 77 Complete records 48 Missing n pts staying>24h in ICU 7 Missing n pt-days for pts>24h in ICU 7 Missing n cvc-days (pts>24h) in ICU, cath.total 24 Missing n cvc-days (pts>24h) in ICU, pt.total 22 *optional b. Septicemia data Total number of septicemia records 5020 Missing micro-organism 7 Missing service where SEP was diagnosed* 105 Missing outcome (follow-up) status 217 Missing outcome (follow-up) date 217 Unlikely delay admission to infection 6 Infection date after discharge date 13 NSIHwin only: Nosocomial judgment out of range 26 Origin SEP out of range 0 Relationship out of range 242 Origin=other infection & no other infection site 229 *replaced by service of admission if available Page 3 Dqc

4 3. TABLES Table 1a : Standard summary A. Denominator data Number of admissions Mean number of admissions per month 953 Number of patient-days Mean length of hospital stay (days)* 7.8 N of admissions in intensive care Mean number of ICU admissions per month 60 N of patient-days in intensive care Mean length of stay in intensive care (days)* 4.3 Number of hemocultures N hemocultures per 1000 patient-days 40.2 *missings excluded B. Septicemia episodes all > Day 2 Total number of septicemia records N SEP with >=1 recognized pathogen (A) N SEP with skin contaminant(s) only of which 2 positive hemocultures (old definition)(b) positive hc + cvc + AB therapy (KD)(C) positive hc, no cvc or AB therapy (deleted)(d) N of septicemia records in analysis(a+b) Whocare 0 0 NSIHwin Nosocomial character (A+B) Not nosocomial Probably nosocomial Definitely nosocomial Incidence a. Hospital-wide all SEP >D2 Incidence per 1000 admissions Incidence per patient-days N sep/100 hemocultures Positive HC % b. Intensive care (all patients) all SEP >D2 Incidence per 1000 admissions Incidence per patient-days Table 1b : KD summary (NSIHwin data) Page 4 Table1

5 A. Denominator data N quarters Number of admissions Number of patient-days Mean length of hospital stay (days)* 7.8 N patients staying>24h in intensive care N of patient-days for pts staying >24h in intensive care Mean length of stay in intensive care (days)* 5.2 Number of catheter-days, patient total CVC days/1000 patient-days* 525 Number of catheter-days, cath.total CVC days/1000 patient-days* 621 *missings excluded B. Septicemia episodes all > Day 2 Total number of septicemia records N SEP with >=1 recognized pathogen (A) N SEP with only skin contaminant(s) of which 2 positive hemocultures (old definition)(b) positive hc + cvc + AB therapy (KD)(C) positive hc, no cvc or AB therapy (deleted) N of septicemia records in analysis(a+b+c) N of primary septicemia Incidence a. Hospital-wide Primary SEP>D2 per 1000 patient-days, hospital b. Intensive care (patients staying>24h) Prim. SEP>D2 on int.care, per 1000 pt-days Cath-ass. SEP>D2 in intensive care, per 1000 cvc-days (pt.total) Cath-ass. SEP>D2 in intensive care, per 1000 cvc-days (cat.total) Page 5 Table1

6 Table 2a: Origin (source) of septicemia Note: SEP>D2, NSIH definition (A+B) Incidence / ptdays Probable (%) Definite (%) Total (%) Catheter-related 260 (7.5) 371 (10.7) 631 (18.2) 1.45 NSIHwin data 260 (7.5) 371 (10.7) 631 (18.2) Central catheter 221 (6.4) 328 (6.4) 549 (15.8) Peripheral catheter 30 (0.9) 13 (0.9) 43 (1.2) Arterial catheter 9 (0.3) 12 (0.3) 21 (0.6) Secondary origin 752 (21.7) 888 (25.6) 1640 (47.2) 3.7 Urinary tract infection 177 (5.1) 384 (11.1) 561 (16.2) Pneumonia 127 (3.7) 114 (3.3) 241 (3.7) Other respiratory tract inf. 98 (2.8) 60 (1.7) 158 (2.8) Inf. gastro-intestinal system 126 (3.6) 82 (2.4) 208 (3.6) Inf. skin/soft tissue 53 (1.5) 43 (1.2) 96 (1.5) Surgical site infection 40 (1.2) 58 (1.7) 98 (1.2) Cardiovascular system inf. 15 (0.4) 16 (0.5) 31 (0.4) Eye/ear/nose/throat/mouth 15 (0.4) 5 (0.1) 20 (0.4) Bone/joint infection 12 (0.3) 11 (0.3) 23 (0.3) Reproductive tract inf. 5 (0.1) 3 (0.1) 8 (0.1) Central nervous system inf. 1 (0.0) 4 (0.1) 5 (0.0) Systemic infection 9 (0.3) 1 (0.0) 10 (0.3) Other infection/ not specified 19 (0.5) 91 (2.6) 110 (0.5) Invasive procedure 48 (1.4) 29 (0.8) 77 (1.4) Foreign body 18 (0.5) 15 (0.4) 33 (0.5) Unknown origin 1200 (34.6) 2.72 TOTAL septicemia >D (100) 7.79 Total NSIHwin data >D (100) Table 2b: Catheter data (optional) Total sep with catheter data 954 Catheter cath-ass.sep sec.sep unkown total Central catheter Peripheral catheter Arterial catheter Catheter-days by catheter type N Mean duration Median duration Central catheters d 10 d Jugular CVC d 11 d Subclavian CVC d 11 d Femoral catheter d 11 d Implanted (Port-a-cath) d 22.5 d Umbilical catheter d 4.5 d Dialysis catheter d 7 d Other/unspecified d 9 d Peripheral catheters d 5 d Arterial catheters d 6.5 d Page 6 Table2

7 Table 3 : Distribution of septicemia by service all >D2 in hospital >D2 in service* Burn 1 (0.0) 1 (0.0) 1 (0.0) General/abdom surg. 362 (7.4) 320 (9.2) 303 (9.4) Cardiovasc.surg 90 (1.8) 81 (2.3) 77 (2.4) Mixed surgical/medic 152 (3.1) 113 (3.3) 108 (3.3) Neurosurgery 47 (1.0) 43 (1.2) 39 (1.2) Orthopedics 110 (2.3) 96 (2.8) 93 (2.9) Plastic surgery 6 (0.1) 5 (0.1) 5 (0.2) Urology 103 (2.1) 59 (1.7) 51 (1.6) Other surgery 39 (0.8) 26 (0.7) 25 (0.8) Geriatrics 564 (11.6) 410 (11.8) 394 (12.2) Gynecology 21 (0.4) 15 (0.4) 14 (0.4) Intensive care 885 (18.2) 754 (21.7) 651 (20.1) Cardiology 212 (4.3) 168 (4.8) 156 (4.8) Endocrinology 14 (0.3) 8 (0.2) 7 (0.2) Internal Medicine 626 (12.8) 404 (11.6) 384 (11.9) Nephrology 118 (2.4) 64 (1.8) 58 (1.8) Oncology/Hematology 485 (9.9) 390 (11.2) 379 (11.7) Pneumology 164 (3.4) 107 (3.1) 100 (3.1) Medicine, other 125 (2.6) 83 (2.4) 77 (2.4) Neonatal Intensive Care 92 (1.9) 82 (2.4) 82 (2.5) Obstetrics 27 (0.6) 14 (0.4) 14 (0.4) Otorhinolaryngology 2 (0.0) 0 (0.0) 0 (0.0) Pediatrics 112 (2.3) 53 (1.5) 52 (1.6) Psychiatry 15 (0.3) 10 (0.3) 10 (0.3) Revalidation 107 (2.2) 93 (2.7) 88 (2.7) Trauma/Emergency 271 (5.6) 16 (0.5) 11 (0.3) Other types 126 (2.6) 56 (1.6) 52 (1.6) TOTAL 4876 (100) 3471 (100) 3231 (100) *NSIHwin only Page 7 Table3

8 Table 4: Clinical data a. Demographics of patients with septicemia 1. Age and gender N % mean age min P25 P50 P75 max Female Male Total Patient origin at admission* N % Other hospital Nursing home Community Total Total NSIHwin data 4918 Missing origin b. Status at end of follow-up (in hospital) 1. Outcome and relationship septicemia to death Outcome <=7 d after SEP (%)(1) >7d after SEP (%)(1) Tot + disch.date (%)(2) Total (%)(2) Alive 683 (19.3) 2861 (80.7) 3544 (76.1) 3589 (76.2) Death 412 (37.0) 701 (63.0) 1113 (23.9) 1121 (23.8) Relationship septicemia to death (NSIHwin) Relationship not verified 155 (34.4) 295 (65.6) 450 (10.1) 451 (9.8) Not related 82 (23.8) 262 (76.2) 344 (7.7) 345 (7.5) Possible relationship 92 (49.2) 95 (50.8) 187 (4.3) 192 (4.2) Definite relationship 66 (74.2) 23 (25.8) 89 (2.0) 90 (2.0) (1) row percentage - (2) column percentage 95%CI Crude mortality (case fatality) rate 23.90% ( ) Mortality % in nosocomial(>d2) SEP % ( ) Mortality % within 7 days after noso-sep 10.10% ( ) Mortality % poss/defin. related to noso-sep 11.40% ( ) 2. Age and sex specific mortality N deaths (mortality %)(2) Age group N(1) F M Total <1 y (12.2) 9 (8.2) 20 (10.0) 1-4 y 76 1 (3.6) 0 (0.0) 1 (1.3) 5-14 y 51 1 (5.3) 2 (6.3) 3 (5.9) y (6.3) 2 (3.1) 7 (4.9) y (11.3) 12 (16.2) 18 (14.2) y (12.9) 20 (12.6) 38 (12.8) y (23.2) 88 (25.6) 143 (24.6) y (20.3) 128 (24.1) 188 (22.8) y (28.5) 212 (29.3) 361 (29.0) y (29.9) 155 (30.2) 311 (30.0) 90+ y (27.1) 8 (25.0) 31 (26.5) Total (23.4) 636 (24.2) 1121 (23.9) (1) Total number of patients in age group (2) N of deaths by sex and age - N of patients in cell=n deaths(% mortality) Page 8 Table4

9 c. Clinical symptoms* age <12m % age >=12m % total % Missing % % % Unknown % % % Fever % % % Chills 2 0.8% % % Hypotension 1 0.4% % % Hypothermia % 0 0.0% % Apnea % 0 0.0% % Bradycardia % 0 0.0% % *NSIHwin only Page 9 Table4

10 Table 5a : Distribution of micro-organisms A. Grouped, in decreasing order of frequency Escherichia spp % Coagulase-neg. staphylococci % Staphylococcus aureus % Streptococcus spp % Klebsiella spp % Enterococcus spp % Pseudomonas spp % Enterobacter spp % Candida spp % Proteus spp % Acinetobacter spp % Bacteroides spp % Serratia spp % Morganella spp % Other/unidentified % Citrobacter spp % Salmonella spp % Haemophilus spp % Stenotrophomonas spp % Neisseria spp % Clostridium spp % Corynebacterium spp % Providencia spp % Saccharomyces spp % Bacillus spp % Fusobacterium spp % Moraxella spp % Peptostreptococcus spp % Aeromonas spp % Listeria spp % Lactobacillus spp % Aerococcus spp % Campylobacter spp % Micrococcus spp % Peptococcus spp % Prevotella spp % Stomatococcus spp % Abiotrophia spp % Burkholderia spp % Capnocytophagia spp % Chryseobacterium spp % Entamoeba spp % Flavobacterium spp % Gemella spp % Other/unspec. yeast % Propionibacterium spp % Achromobacter spp % Actinomyces spp % Agrobacterium spp % Comamomas spp % Cryptococcus spp % Hafnia spp % Leuconostoc spp % Other gram-neg. bacilli, non-ferm % Other gram-pos. aerobic bacilli % Other gram-pos. cocci, aerobic % Pasteurella spp % Total % B. Detailed, in alphabetic order Page 10 Table5a

11 ABIOTROPHIA ADIACENS % ACHROMOBACTER XYLOSOXIDANS % ACINETOBACTER BAUMANNII % ACINETOBACTER CALCOACETICUS % ACINETOBACTER HAEMOLYTICUS % ACINETOBACTER JOHNSONII % ACINETOBACTER JUNII % ACINETOBACTER LWOFFI % ACINETOBACTER SPECIES, NOT SPECIFIED % ACTINOMYCES NAESLUNDII % AEROCOCCUS SPECIES, NOT SPECIFIED % AEROCOCCUS VIRIDANS % AEROMONAS HYDROPHILA % AGROBACTERIUM RADIOBACTER % ANAEROBES, NOT SPECIFIED % ARCANOBACTERIUM HAEMOLYTICUM % BACILLUS CEREUS % BACILLUS SPECIES, NOT SPECIFIED % BACTEROIDES AMYLOPHILUS % BACTEROIDES CAPILLOSUS % BACTEROIDES EGGERTHII % BACTEROIDES FRAGILIS % BACTEROIDES OVATUS % BACTEROIDES RUMINICOLA SUBSPECIES BREVIS % BACTEROIDES SPECIES, NOT SPECIFIED % BACTEROIDES THETAIOTAOMICRON % BACTEROIDES UNIFORMIS % BACTEROIDES VULGATUS % BIFIDOBACTERIUM SPECIES, NOT SPECIFIED % BURKHOLDERIA CEPACIA % CAMPYLOBACTER JEJUNI % CAMPYLOBACTER SPECIES, NOT SPECIFIED % CANDIDA ALBICANS % CANDIDA GLABRATA % CANDIDA GUILLIERMONDII % CANDIDA KEFYR % CANDIDA KRUSEI % CANDIDA LUSITANIAE % CANDIDA PARAPSILOSIS % CANDIDA SPECIES, NOT SPECIFIED % CANDIDA TROPICALIS % CAPNOCYTOPHAGIA SPECIES, NOT SPECIFIED % CAPNOCYTOPHAGIA SPUTIGENA % CHROMOBACTERIUM SPECIES, NOT SPECIFIED % CHRYSEOBACTERIUM MENINGOSEPTICUM % CHRYSEOBACTERIUM SPECIES, NOT SPECIFIED % CITROBACTER BRAAKII % CITROBACTER DIVERSUS % CITROBACTER FREUNDII % CITROBACTER SPECIES, NOT SPECIFIED % CLOSTRIDIUM DIFFICILE % CLOSTRIDIUM PERFRINGENS % CLOSTRIDIUM SPECIES, NOT SPECIFIED % CLOSTRIDIUM TETANI % COAGULASE-NEGATIVE STAFYLOCOCCI, NOT SPECIFIED % COMAMOMAS ACIDOVORANS % CORYNEBACTERIUM JEIKEIUM % CORYNEBACTERIUM PSEUDODIPHTERITICUM % CORYNEBACTERIUM SPECIES, NOT SPECIFIED % CORYNEBACTERIUM XEROSIS % CRYPTOCOCCUS NEOFORMANS % ECHINOCOCCUS GRANULOSUS % Page 11 Table5a

12 ENDOLIMAX NANA % ENTAMOEBA COLI % ENTAMOEBA HISTOLYTICA % ENTEROBACTER AEROGENES % ENTEROBACTER AMNIGENUS % ENTEROBACTER CLOACAE % ENTEROBACTER SAKAZAKII % ENTEROBACTER SPECIES, NOT SPECIFIED % ENTEROBIUS SPECIES, NOT SPECIFIED % ENTEROCOCCUS AVIUM % ENTEROCOCCUS DURANS % ENTEROCOCCUS FAECALIS % ENTEROCOCCUS FAECIUM % ENTEROCOCCUS SPECIES, NOT SPECIFIED % ENTEROPATHOGENIC ESCHERICHIA COLI % ERYSIPELOTHRIX RHUSIOPATHIAE % ESCHERICHIA COLI % FLAVOBACTERIUM INDOLOGENES % FLAVOBACTERIUM SPECIES, NOT SPECIFIED % FUSARIUM SPECIES % FUSOBACTERIUM NECROPHORUM % FUSOBACTERIUM NUCLEATUM % FUSOBACTERIUM SPECIES, NOT SPECIFIED % G-BAC, NON ENTEROBACTERIACEAE, NOT SPEC % GEMELLA MORBILLORUM % GEMELLA SPECIES, NOT SPECIFIED % GRAM NEGATIVE COCCI, NOT SPECIFIED % GRAM POSITIVE BACILLI, NOT SPECIFIED % GRAM POSITIVE COCCI, NOT SPECIFIED % HAEMOPHILUS AEGYPTIUS % HAEMOPHILUS APHROPHILUS % HAEMOPHILUS INFLUENZAE % HAFNIA ALVEI % KINGELLA KINGAE % KLEBSIELLA ORNITHINOLYTICA % KLEBSIELLA OXYTOCA % KLEBSIELLA OZAENAE % KLEBSIELLA PNEUMONIAE % KLEBSIELLA SPECIES, NOT SPECIFIED % LACTOBACILLUS SPECIES, NOT SPECIFIED % LEPTOTRICHIA SPECIES, NOT SPECIFIED % LEUCONOSTOC SPECIES % LISTERIA MONOCYTOGENES % LISTERIA SPECIES, NOT SPECIFIED % MICRO-ORGANISM NOT IDENTIFIED OR NOT FOUND % MICROCOCCUS SPECIES % MORAXELLA CATARRHALIS % MORAXELLA SPECIES, NOT SPECIFIED % MORGANELLA MORGANII % NEISSERIA GONORRHOEAE % NEISSERIA MENINGITIDIS % NEISSERIA SPECIES, NOT SPECIFIED % NUTRITIONNALY VARIANT STREPTOCOCCI % OTHER BACTERIA, NOT SPECIFIED % PANTOEA AGGLOMERANS % PASTEURELLA MULTOCIDA % PEPTOCOCCUS SPECIES, NOT SPECIFIED % PEPTOSTREPTOCOCCUS ANAEROBIUS % PEPTOSTREPTOCOCCUS MICROS % PEPTOSTREPTOCOCCUS SPECIES, NOT SPECIFIED % PREVOTELLA MELANINOGENICA % PREVOTELLA ORALIS % Page 12 Table5a

13 PROPIONIBACTERIUM ACNES % PROPIONIBACTERIUM SPECIES, NOT SPECIFIED % PROTEUS MIRABILIS % PROTEUS SPECIES, NOT SPECIFIED % PROTEUS VULGARIS % PROVIDENCIA RETTGERI % PROVIDENCIA SPECIES, NOT SPECIFIED % PROVIDENCIA STUARTII % PSEUDOMONAS AERUGINOSA % PSEUDOMONAS DIMINUTA % PSEUDOMONAS MALTOPHILIA % PSEUDOMONAS PAUCIMOBILIS % PSEUDOMONAS PUTIDA % PSEUDOMONAS SPECIES, NOT SPECIFIED % PSEUDOMONAS STUTZERI % PSEUDOMONAS VESICULARIS % RHODOTORULA SPECIES, NOT SPECIFIED % ROTHIA SPECIES, NOT SPECIFIED % SACCHAROMYCES CEREVISIAE % SALMONELLA ENTERITIDIS % SALMONELLA OF GROUP B % SALMONELLA OF GROUP C % SALMONELLA OF GROUP D % SALMONELLA PARATYPHI A % SALMONELLA SPECIES, NOT SPECIFIED % SALMONELLA STANLEY % SALMONELLA TYPHI % SALMONELLA TYPHIMURIUM % SERRATIA LIQUEFACIENS % SERRATIA MARCESCENS % SERRATIA SPECIES, NOT SPECIFIED % SPHINGOBACTERIUM SPECIES, NOT SPECIFIED % STAPHYLOCOCCUS AUREUS % STAPHYLOCOCCUS AURICULARIS % STAPHYLOCOCCUS CAPITIS % STAPHYLOCOCCUS COHNII % STAPHYLOCOCCUS EPIDERMIDIS % STAPHYLOCOCCUS HAEMOLYTICUS % STAPHYLOCOCCUS HOMINIS % STAPHYLOCOCCUS LENTUS % STAPHYLOCOCCUS SACCHAROLYTICUS % STAPHYLOCOCCUS SAPROPHYTICUS % STAPHYLOCOCCUS SCHLEIFERI % STAPHYLOCOCCUS SPECIES, NOT SPECIFIED % STAPHYLOCOCCUS WARNERI % STAPHYLOCOCCUS XYLOSUS % STAPHYLOCOCCUS, COAGULASE NEGATIVE % STENOTROPHOMONAS MALTOPHILIA % STOMATOCOCCUS MUCILAGINOSUS % STREPTOCOCCI, ALPHA-HEMOLYTIC % STREPTOCOCCI, BETA-HEMOLYTIC % STREPTOCOCCI, BETA-HEMOLYTIC OF GROUP A % STREPTOCOCCI, BETA-HEMOLYTIC OF GROUP B % STREPTOCOCCI, BETA-HEMOLYTIC OF GROUP C % STREPTOCOCCI, BETA-HEMOLYTIC OF GROUP F % STREPTOCOCCI, BETA-HEMOLYTIC OF GROUP G % STREPTOCOCCI, GAMMA-HEMOLYTIC % STREPTOCOCCUS ACIDOMINIMUS % STREPTOCOCCUS AGALACTIAE % STREPTOCOCCUS ANGINOSUS % STREPTOCOCCUS BOVIS % STREPTOCOCCUS MILLERI % Page 13 Table5a

14 STREPTOCOCCUS MITIS % STREPTOCOCCUS OF GROUP D % STREPTOCOCCUS PNEUMONIAE % STREPTOCOCCUS PYOGENES % STREPTOCOCCUS SALIVARIUS % STREPTOCOCCUS SANGUIS % STREPTOCOCCUS SPECIES, NOT SPECIFIED % STREPTOCOCCUS SUIS % STREPTOCOCCUS VIRIDANS % STREPTOMYCES SPECIES % YEASTS % Total % Page 14 Table5a

15 Table 5b : Distribution of micro-organisms by service A. Grouped, in decreasing order of frequency Burn Coagulase-neg. staphylococci % Total % General/abdom surg. Escherichia spp % Coagulase-neg. staphylococci % Klebsiella spp % Staphylococcus aureus % Enterobacter spp % Enterococcus spp % Streptococcus spp % Candida spp % Pseudomonas spp % Bacteroides spp % Proteus spp % Serratia spp % Acinetobacter spp % Morganella spp % Clostridium spp % Fusobacterium spp % Other/unidentified % Salmonella spp % Stenotrophomonas spp % Aeromonas spp % Bacillus spp % Citrobacter spp % Flavobacterium spp % Other gram-pos. aerobic bacilli % Providencia spp % Total % Cardiovasc.surg Escherichia spp % Staphylococcus aureus % Coagulase-neg. staphylococci % Klebsiella spp % Enterobacter spp % Pseudomonas spp % Enterococcus spp % Serratia spp % Streptococcus spp % Proteus spp % Candida spp % Morganella spp % Acinetobacter spp % Entamoeba spp % Other/unspec. yeast % Salmonella spp % Total % Page 15 Table5b-A

16 Mixed surgical/medic Escherichia spp % Staphylococcus aureus % Coagulase-neg. staphylococci % Klebsiella spp % Streptococcus spp % Candida spp % Enterobacter spp % Enterococcus spp % Acinetobacter spp % Other/unidentified % Proteus spp % Haemophilus spp % Serratia spp % Achromobacter spp % Bacteroides spp % Burkholderia spp % Campylobacter spp % Neisseria spp % Pseudomonas spp % Saccharomyces spp % Salmonella spp % Total % Neurosurgery Escherichia spp % Staphylococcus aureus % Coagulase-neg. staphylococci % Klebsiella spp % Enterobacter spp % Enterococcus spp % Providencia spp % Pseudomonas spp % Candida spp % Morganella spp % Proteus spp % Stenotrophomonas spp % Streptococcus spp % Total % Orthopedics Escherichia spp % Staphylococcus aureus % Coagulase-neg. staphylococci % Streptococcus spp % Candida spp % Acinetobacter spp % Enterobacter spp % Klebsiella spp % Proteus spp % Pseudomonas spp % Enterococcus spp % Citrobacter spp % Peptostreptococcus spp % Serratia spp % Page 16 Table5b-A

17 Total % Plastic surgery Coagulase-neg. staphylococci % Candida spp % Enterococcus spp % Escherichia spp % Klebsiella spp % Total % Urology Escherichia spp % Klebsiella spp % Staphylococcus aureus % Streptococcus spp % Coagulase-neg. staphylococci % Proteus spp % Enterococcus spp % Pseudomonas spp % Bacteroides spp % Enterobacter spp % Providencia spp % Acinetobacter spp % Candida spp % Haemophilus spp % Moraxella spp % Neisseria spp % Serratia spp % Stenotrophomonas spp % Total % Other surgery Escherichia spp % Staphylococcus aureus % Coagulase-neg. staphylococci % Enterococcus spp % Klebsiella spp % Enterobacter spp % Streptococcus spp % Proteus spp % Pseudomonas spp % Total % Geriatrics Escherichia spp % Staphylococcus aureus % Coagulase-neg. staphylococci % Streptococcus spp % Klebsiella spp % Enterococcus spp % Proteus spp % Candida spp % Enterobacter spp % Pseudomonas spp % Acinetobacter spp % Page 17 Table5b-A

18 Bacteroides spp % Serratia spp % Citrobacter spp % Morganella spp % Other/unidentified % Saccharomyces spp % Haemophilus spp % Salmonella spp % Aerococcus spp % Bacillus spp % Campylobacter spp % Clostridium spp % Corynebacterium spp % Fusobacterium spp % Micrococcus spp % Peptostreptococcus spp % Propionibacterium spp % Providencia spp % Stomatococcus spp % Total % Gynecology Escherichia spp % Staphylococcus aureus % Streptococcus spp % Acinetobacter spp % Bacteroides spp % Enterobacter spp % Enterococcus spp % Klebsiella spp % Neisseria spp % Other/unidentified % Peptostreptococcus spp % Total % Intensive care Coagulase-neg. staphylococci % Escherichia spp % Enterococcus spp % Pseudomonas spp % Staphylococcus aureus % Klebsiella spp % Candida spp % Streptococcus spp % Enterobacter spp % Bacteroides spp % Serratia spp % Morganella spp % Proteus spp % Acinetobacter spp % Citrobacter spp % Other/unidentified % Neisseria spp % Stenotrophomonas spp % Clostridium spp % Page 18 Table5b-A

19 Corynebacterium spp % Peptococcus spp % Providencia spp % Salmonella spp % Aerococcus spp % Burkholderia spp % Capnocytophagia spp % Chryseobacterium spp % Flavobacterium spp % Haemophilus spp % Lactobacillus spp % Moraxella spp % Peptostreptococcus spp % Saccharomyces spp % Total % Cardiology Escherichia spp % Staphylococcus aureus % Streptococcus spp % Coagulase-neg. staphylococci % Klebsiella spp % Enterococcus spp % Enterobacter spp % Acinetobacter spp % Candida spp % Proteus spp % Pseudomonas spp % Other/unidentified % Serratia spp % Morganella spp % Cryptococcus spp % Fusobacterium spp % Micrococcus spp % Providencia spp % Salmonella spp % Stomatococcus spp % Total % Endocrinology Staphylococcus aureus % Acinetobacter spp % Coagulase-neg. staphylococci % Escherichia spp % Aeromonas spp % Bacillus spp % Comamomas spp % Pasteurella spp % Salmonella spp % Total % Internal Medicine Escherichia spp % Coagulase-neg. staphylococci % Staphylococcus aureus % Page 19 Table5b-A

20 Streptococcus spp % Klebsiella spp % Enterococcus spp % Enterobacter spp % Pseudomonas spp % Candida spp % Proteus spp % Bacteroides spp % Acinetobacter spp % Citrobacter spp % Serratia spp % Other/unidentified % Clostridium spp % Listeria spp % Salmonella spp % Aeromonas spp % Haemophilus spp % Morganella spp % Neisseria spp % Abiotrophia spp % Actinomyces spp % Corynebacterium spp % Gemella spp % Moraxella spp % Peptostreptococcus spp % Propionibacterium spp % Saccharomyces spp % Stenotrophomonas spp % Stomatococcus spp % Total % Nephrology Escherichia spp % Staphylococcus aureus % Coagulase-neg. staphylococci % Enterococcus spp % Klebsiella spp % Enterobacter spp % Streptococcus spp % Pseudomonas spp % Candida spp % Acinetobacter spp % Haemophilus spp % Proteus spp % Serratia spp % Citrobacter spp % Fusobacterium spp % Morganella spp % Peptostreptococcus spp % Salmonella spp % Stenotrophomonas spp % Total % Oncology/Hematology Coagulase-neg. staphylococci % Page 20 Table5b-A

21 Escherichia spp % Staphylococcus aureus % Streptococcus spp % Enterococcus spp % Pseudomonas spp % Klebsiella spp % Enterobacter spp % Candida spp % Acinetobacter spp % Bacteroides spp % Serratia spp % Stenotrophomonas spp % Proteus spp % Citrobacter spp % Bacillus spp % Clostridium spp % Corynebacterium spp % Neisseria spp % Other/unidentified % Lactobacillus spp % Moraxella spp % Morganella spp % Prevotella spp % Abiotrophia spp % Aerococcus spp % Aeromonas spp % Agrobacterium spp % Capnocytophagia spp % Chryseobacterium spp % Fusobacterium spp % Leuconostoc spp % Micrococcus spp % Other gram-neg. bacilli, non-ferm % Other gram-pos. cocci, aerobic % Saccharomyces spp % Salmonella spp % Total % Pneumology Escherichia spp % Streptococcus spp % Staphylococcus aureus % Coagulase-neg. staphylococci % Candida spp % Pseudomonas spp % Enterococcus spp % Klebsiella spp % Acinetobacter spp % Serratia spp % Enterobacter spp % Bacteroides spp % Salmonella spp % Other/unidentified % Proteus spp % Total % Page 21 Table5b-A

22 Medicine, other Escherichia spp % Coagulase-neg. staphylococci % Klebsiella spp % Staphylococcus aureus % Streptococcus spp % Enterobacter spp % Pseudomonas spp % Enterococcus spp % Candida spp % Proteus spp % Acinetobacter spp % Serratia spp % Campylobacter spp % Listeria spp % Morganella spp % Neisseria spp % Total % Neonatal Intensive Care Coagulase-neg. staphylococci % Staphylococcus aureus % Enterococcus spp % Escherichia spp % Klebsiella spp % Streptococcus spp % Enterobacter spp % Candida spp % Acinetobacter spp % Corynebacterium spp % Haemophilus spp % Proteus spp % Pseudomonas spp % Total % Obstetrics Escherichia spp % Streptococcus spp % Staphylococcus aureus % Enterococcus spp % Other/unidentified % Klebsiella spp % Neisseria spp % Peptococcus spp % Prevotella spp % Proteus spp % Pseudomonas spp % Total % Otorhinolaryngology Coagulase-neg. staphylococci % Escherichia spp % Total % Page 22 Table5b-A

23 Pediatrics Streptococcus spp % Escherichia spp % Staphylococcus aureus % Coagulase-neg. staphylococci % Enterobacter spp % Klebsiella spp % Pseudomonas spp % Enterococcus spp % Haemophilus spp % Candida spp % Citrobacter spp % Corynebacterium spp % Lactobacillus spp % Neisseria spp % Other/unidentified % Proteus spp % Salmonella spp % Total % Psychiatry Coagulase-neg. staphylococci % Escherichia spp % Klebsiella spp % Streptococcus spp % Enterobacter spp % Enterococcus spp % Salmonella spp % Stenotrophomonas spp % Total % Revalidation Escherichia spp % Coagulase-neg. staphylococci % Staphylococcus aureus % Proteus spp % Streptococcus spp % Klebsiella spp % Bacteroides spp % Candida spp % Pseudomonas spp % Enterobacter spp % Acinetobacter spp % Entamoeba spp % Enterococcus spp % Moraxella spp % Other/unspec. yeast % Total % Trauma/Emergency Escherichia spp % Streptococcus spp % Staphylococcus aureus % Coagulase-neg. staphylococci % Klebsiella spp % Page 23 Table5b-A

24 Enterococcus spp % Proteus spp % Pseudomonas spp % Other/unidentified % Citrobacter spp % Enterobacter spp % Acinetobacter spp % Candida spp % Haemophilus spp % Bacteroides spp % Gemella spp % Hafnia spp % Listeria spp % Providencia spp % Salmonella spp % Serratia spp % Total % Other types Escherichia spp % Staphylococcus aureus % Streptococcus spp % Coagulase-neg. staphylococci % Enterococcus spp % Klebsiella spp % Enterobacter spp % Pseudomonas spp % Acinetobacter spp % Bacteroides spp % Citrobacter spp % Morganella spp % Proteus spp % Candida spp % Clostridium spp % Haemophilus spp % Serratia spp % Total % Page 24 Table5b-A

25 B. Detailed, in alphabetic order Burn STAPHYLOCOCCUS EPIDERMIDIS % Total % General/abdom surg. ACINETOBACTER BAUMANNII % ACINETOBACTER HAEMOLYTICUS % ACINETOBACTER LWOFFI % ACINETOBACTER SPECIES, NOT SPECIFIED % AEROMONAS HYDROPHILA % BACILLUS CEREUS % BACTEROIDES FRAGILIS % BACTEROIDES RUMINICOLA SUBSPECIES BREVIS % BACTEROIDES SPECIES, NOT SPECIFIED % CANDIDA ALBICANS % CANDIDA GLABRATA % CANDIDA KEFYR % CANDIDA PARAPSILOSIS % CANDIDA SPECIES, NOT SPECIFIED % CITROBACTER FREUNDII % CLOSTRIDIUM SPECIES, NOT SPECIFIED % CLOSTRIDIUM TETANI % COAGULASE-NEGATIVE STAFYLOCOCCI, NOT SPE % ENTEROBACTER AEROGENES % ENTEROBACTER CLOACAE % ENTEROCOCCUS AVIUM % ENTEROCOCCUS FAECALIS % ENTEROCOCCUS FAECIUM % ENTEROCOCCUS SPECIES, NOT SPECIFIED % ERYSIPELOTHRIX RHUSIOPATHIAE % ESCHERICHIA COLI % FLAVOBACTERIUM SPECIES, NOT SPECIFIED % FUSOBACTERIUM NUCLEATUM % GRAM POSITIVE BACILLI, NOT SPECIFIED % KLEBSIELLA ORNITHINOLYTICA % KLEBSIELLA OXYTOCA % KLEBSIELLA PNEUMONIAE % MICRO-ORGANISM NOT IDENTIFIED OR NOT FOU % MORGANELLA MORGANII % PROTEUS MIRABILIS % PROTEUS SPECIES, NOT SPECIFIED % PROVIDENCIA STUARTII % PSEUDOMONAS AERUGINOSA % PSEUDOMONAS DIMINUTA % PSEUDOMONAS PAUCIMOBILIS % PSEUDOMONAS STUTZERI % SALMONELLA TYPHI % SALMONELLA TYPHIMURIUM % SERRATIA MARCESCENS % STAPHYLOCOCCUS AUREUS % STAPHYLOCOCCUS CAPITIS % STAPHYLOCOCCUS EPIDERMIDIS % STAPHYLOCOCCUS HAEMOLYTICUS % Page 25 Table5b-B

26 STAPHYLOCOCCUS HOMINIS % STAPHYLOCOCCUS SACCHAROLYTICUS % STAPHYLOCOCCUS SCHLEIFERI % STAPHYLOCOCCUS SPECIES, NOT SPECIFIED % STAPHYLOCOCCUS, COAGULASE NEGATIVE % STENOTROPHOMONAS MALTOPHILIA % STREPTOCOCCI, BETA-HEMOLYTIC % STREPTOCOCCUS AGALACTIAE % STREPTOCOCCUS ANGINOSUS % STREPTOCOCCUS BOVIS % STREPTOCOCCUS MILLERI % STREPTOCOCCUS MITIS % STREPTOCOCCUS PNEUMONIAE % STREPTOCOCCUS SPECIES, NOT SPECIFIED % STREPTOCOCCUS VIRIDANS % Total % Cardiovasc.surg ACINETOBACTER BAUMANNII % CANDIDA GLABRATA % CANDIDA PARAPSILOSIS % COAGULASE-NEGATIVE STAFYLOCOCCI, NOT SPE % ENTAMOEBA HISTOLYTICA % ENTEROBACTER AEROGENES % ENTEROBACTER CLOACAE % ENTEROBACTER SPECIES, NOT SPECIFIED % ENTEROCOCCUS FAECALIS % ESCHERICHIA COLI % KLEBSIELLA OXYTOCA % KLEBSIELLA PNEUMONIAE % MORGANELLA MORGANII % PROTEUS MIRABILIS % PROTEUS VULGARIS % PSEUDOMONAS AERUGINOSA % SALMONELLA STANLEY % SERRATIA MARCESCENS % STAPHYLOCOCCUS AUREUS % STAPHYLOCOCCUS EPIDERMIDIS % STAPHYLOCOCCUS HAEMOLYTICUS % STAPHYLOCOCCUS SPECIES, NOT SPECIFIED % STAPHYLOCOCCUS XYLOSUS % STAPHYLOCOCCUS, COAGULASE NEGATIVE % STREPTOCOCCI, BETA-HEMOLYTIC OF GROUP A % STREPTOCOCCUS AGALACTIAE % STREPTOCOCCUS BOVIS % STREPTOCOCCUS PNEUMONIAE % STREPTOCOCCUS PYOGENES % YEASTS % Total % Mixed surgical/medic ACHROMOBACTER XYLOSOXIDANS % ACINETOBACTER BAUMANNII % ACINETOBACTER HAEMOLYTICUS % ACINETOBACTER SPECIES, NOT SPECIFIED % Page 26 Table5b-B

27 BACTEROIDES SPECIES, NOT SPECIFIED % BURKHOLDERIA CEPACIA % CAMPYLOBACTER JEJUNI % CANDIDA ALBICANS % CANDIDA GLABRATA % CANDIDA GUILLIERMONDII % CANDIDA PARAPSILOSIS % CANDIDA TROPICALIS % COAGULASE-NEGATIVE STAFYLOCOCCI, NOT SPE % ENTEROBACTER AEROGENES % ENTEROBACTER CLOACAE % ENTEROBIUS SPECIES, NOT SPECIFIED % ENTEROCOCCUS FAECALIS % ESCHERICHIA COLI % HAEMOPHILUS INFLUENZAE % KLEBSIELLA OXYTOCA % KLEBSIELLA PNEUMONIAE % MICRO-ORGANISM NOT IDENTIFIED OR NOT FOU % NEISSERIA MENINGITIDIS % PANTOEA AGGLOMERANS % PROTEUS MIRABILIS % PSEUDOMONAS AERUGINOSA % SACCHAROMYCES CEREVISIAE % SALMONELLA PARATYPHI A % SERRATIA MARCESCENS % STAPHYLOCOCCUS AUREUS % STAPHYLOCOCCUS EPIDERMIDIS % STAPHYLOCOCCUS HOMINIS % STAPHYLOCOCCUS SPECIES, NOT SPECIFIED % STAPHYLOCOCCUS, COAGULASE NEGATIVE % STREPTOCOCCI, BETA-HEMOLYTIC OF GROUP A % STREPTOCOCCUS ACIDOMINIMUS % STREPTOCOCCUS BOVIS % STREPTOCOCCUS MITIS % STREPTOCOCCUS PNEUMONIAE % STREPTOCOCCUS PYOGENES % STREPTOCOCCUS VIRIDANS % Total % Neurosurgery CANDIDA ALBICANS % ENTEROBACTER AEROGENES % ENTEROBACTER CLOACAE % ENTEROCOCCUS FAECALIS % ENTEROCOCCUS SPECIES, NOT SPECIFIED % ESCHERICHIA COLI % KLEBSIELLA OXYTOCA % KLEBSIELLA PNEUMONIAE % MORGANELLA MORGANII % PROTEUS MIRABILIS % PROVIDENCIA SPECIES, NOT SPECIFIED % PROVIDENCIA STUARTII % PSEUDOMONAS AERUGINOSA % STAPHYLOCOCCUS AUREUS % STAPHYLOCOCCUS EPIDERMIDIS % Page 27 Table5b-B

28 STAPHYLOCOCCUS WARNERI % STAPHYLOCOCCUS, COAGULASE NEGATIVE % STENOTROPHOMONAS MALTOPHILIA % STREPTOCOCCUS PNEUMONIAE % Total % Orthopedics ACINETOBACTER BAUMANNII % ACINETOBACTER HAEMOLYTICUS % ACINETOBACTER LWOFFI % CANDIDA ALBICANS % CANDIDA PARAPSILOSIS % CANDIDA TROPICALIS % CITROBACTER FREUNDII % COAGULASE-NEGATIVE STAFYLOCOCCI, NOT SPE % ENTEROBACTER AEROGENES % ENTEROBACTER CLOACAE % ENTEROCOCCUS FAECALIS % ENTEROCOCCUS FAECIUM % ESCHERICHIA COLI % KLEBSIELLA ORNITHINOLYTICA % KLEBSIELLA OXYTOCA % KLEBSIELLA PNEUMONIAE % PEPTOSTREPTOCOCCUS SPECIES, NOT SPECIFIE % PROTEUS MIRABILIS % PROTEUS SPECIES, NOT SPECIFIED % PROTEUS VULGARIS % PSEUDOMONAS AERUGINOSA % SERRATIA MARCESCENS % STAPHYLOCOCCUS AUREUS % STAPHYLOCOCCUS CAPITIS % STAPHYLOCOCCUS EPIDERMIDIS % STAPHYLOCOCCUS, COAGULASE NEGATIVE % STREPTOCOCCUS BOVIS % STREPTOCOCCUS OF GROUP D % STREPTOCOCCUS PNEUMONIAE % STREPTOCOCCUS PYOGENES % STREPTOCOCCUS SANGUIS % STREPTOCOCCUS VIRIDANS % Total % Plastic surgery CANDIDA GLABRATA % ENTEROCOCCUS FAECALIS % ESCHERICHIA COLI % KLEBSIELLA PNEUMONIAE % STAPHYLOCOCCUS EPIDERMIDIS % STAPHYLOCOCCUS HAEMOLYTICUS % STAPHYLOCOCCUS HOMINIS % Total % Urology ACINETOBACTER BAUMANNII % BACTEROIDES FRAGILIS % CANDIDA ALBICANS % Page 28 Table5b-B

29 COAGULASE-NEGATIVE STAFYLOCOCCI, NOT SPE % ENTEROBACTER AEROGENES % ENTEROBACTER CLOACAE % ENTEROCOCCUS FAECALIS % ENTEROCOCCUS FAECIUM % ESCHERICHIA COLI % HAEMOPHILUS INFLUENZAE % KLEBSIELLA OXYTOCA % KLEBSIELLA PNEUMONIAE % MORAXELLA SPECIES, NOT SPECIFIED % NEISSERIA MENINGITIDIS % PROTEUS MIRABILIS % PROVIDENCIA RETTGERI % PSEUDOMONAS AERUGINOSA % SERRATIA MARCESCENS % STAPHYLOCOCCUS AUREUS % STAPHYLOCOCCUS CAPITIS % STAPHYLOCOCCUS EPIDERMIDIS % STAPHYLOCOCCUS, COAGULASE NEGATIVE % STENOTROPHOMONAS MALTOPHILIA % STREPTOCOCCI, BETA-HEMOLYTIC OF GROUP A % STREPTOCOCCUS MITIS % STREPTOCOCCUS PNEUMONIAE % STREPTOCOCCUS VIRIDANS % Total % Other surgery COAGULASE-NEGATIVE STAFYLOCOCCI, NOT SPE % ENTEROBACTER AEROGENES % ENTEROCOCCUS FAECALIS % ENTEROCOCCUS SPECIES, NOT SPECIFIED % ESCHERICHIA COLI % KLEBSIELLA OXYTOCA % KLEBSIELLA PNEUMONIAE % PROTEUS MIRABILIS % PSEUDOMONAS AERUGINOSA % STAPHYLOCOCCUS AUREUS % STAPHYLOCOCCUS CAPITIS % STAPHYLOCOCCUS EPIDERMIDIS % STAPHYLOCOCCUS, COAGULASE NEGATIVE % STREPTOCOCCUS BOVIS % STREPTOCOCCUS SUIS % Total % Geriatrics ACINETOBACTER BAUMANNII % ACINETOBACTER SPECIES, NOT SPECIFIED % AEROCOCCUS VIRIDANS % ANAEROBES, NOT SPECIFIED % BACILLUS CEREUS % BACTEROIDES FRAGILIS % BACTEROIDES SPECIES, NOT SPECIFIED % BACTEROIDES UNIFORMIS % BACTEROIDES VULGATUS % CAMPYLOBACTER SPECIES, NOT SPECIFIED % Page 29 Table5b-B

30 CANDIDA ALBICANS % CANDIDA GLABRATA % CANDIDA SPECIES, NOT SPECIFIED % CANDIDA TROPICALIS % CITROBACTER BRAAKII % CITROBACTER DIVERSUS % CITROBACTER FREUNDII % CITROBACTER SPECIES, NOT SPECIFIED % CLOSTRIDIUM PERFRINGENS % COAGULASE-NEGATIVE STAFYLOCOCCI, NOT SPE % CORYNEBACTERIUM SPECIES, NOT SPECIFIED % ECHINOCOCCUS GRANULOSUS % ENTEROBACTER AEROGENES % ENTEROBACTER CLOACAE % ENTEROCOCCUS DURANS % ENTEROCOCCUS FAECALIS % ENTEROCOCCUS FAECIUM % ENTEROCOCCUS SPECIES, NOT SPECIFIED % ESCHERICHIA COLI % FUSOBACTERIUM NECROPHORUM % GRAM POSITIVE BACILLI, NOT SPECIFIED % HAEMOPHILUS INFLUENZAE % KLEBSIELLA OXYTOCA % KLEBSIELLA OZAENAE % KLEBSIELLA PNEUMONIAE % KLEBSIELLA SPECIES, NOT SPECIFIED % MICROCOCCUS SPECIES % MORGANELLA MORGANII % OTHER BACTERIA, NOT SPECIFIED % PEPTOSTREPTOCOCCUS ANAEROBIUS % PROPIONIBACTERIUM ACNES % PROTEUS MIRABILIS % PROTEUS SPECIES, NOT SPECIFIED % PROVIDENCIA STUARTII % PSEUDOMONAS AERUGINOSA % PSEUDOMONAS PAUCIMOBILIS % ROTHIA SPECIES, NOT SPECIFIED % SACCHAROMYCES CEREVISIAE % SALMONELLA ENTERITIDIS % SALMONELLA OF GROUP D % SALMONELLA TYPHIMURIUM % SERRATIA MARCESCENS % STAPHYLOCOCCUS AUREUS % STAPHYLOCOCCUS CAPITIS % STAPHYLOCOCCUS COHNII % STAPHYLOCOCCUS EPIDERMIDIS % STAPHYLOCOCCUS HAEMOLYTICUS % STAPHYLOCOCCUS HOMINIS % STAPHYLOCOCCUS SACCHAROLYTICUS % STAPHYLOCOCCUS SCHLEIFERI % STAPHYLOCOCCUS SPECIES, NOT SPECIFIED % STAPHYLOCOCCUS WARNERI % STAPHYLOCOCCUS, COAGULASE NEGATIVE % STOMATOCOCCUS MUCILAGINOSUS % STREPTOCOCCI, BETA-HEMOLYTIC OF GROUP B % Page 30 Table5b-B

SUPPLEMENTARY MATERIAL

SUPPLEMENTARY MATERIAL SUPPLEMENTARY MATERIAL (A) Further inclusion criteria and categorisation of ICD-10 diagnostic codes Pneumonia: A310 Pulmonary mycobacterial infection A420 Pulmonary actinomycosis A481 Legionnaires' disease

More information

General Bacteriology 1 (5080) and 2 (5081). List of microbes included in the specimens linked to the corresponding photo replies since

General Bacteriology 1 (5080) and 2 (5081). List of microbes included in the specimens linked to the corresponding photo replies since External Quality Assessment Scheme General Bacteriology 1 (5080) and 2 (5081). List of microbes included in the specimens linked to the corresponding photo replies since 1.1.2008. Microbe Round/ Specimen

More information

General Bacteriology 1 and 2. List of samples and the microbes linked to the corresponding photo replies since

General Bacteriology 1 and 2. List of samples and the microbes linked to the corresponding photo replies since External Quality Assessment Scheme General Bacteriology 1 and 2. List of samples and the microbes linked to the corresponding photo replies since 1.1.2008 Microbe Survey/ Sample Specimen type. Patient

More information

Cefotaxime Rationale for the EUCAST clinical breakpoints, version th September 2010

Cefotaxime Rationale for the EUCAST clinical breakpoints, version th September 2010 Cefotaxime Rationale for the EUCAST clinical breakpoints, version 1.0 26 th September 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European

More information

Microsan rx Anti-Microbial Healthcare Professional Soap. Organism Positives ATCC #

Microsan rx Anti-Microbial Healthcare Professional Soap. Organism Positives ATCC # : Contact Time: 30 seconds 17,500 ppm. PCMX active Organism Positives ATCC # Acinetobacter calcoaceticus var. anitratus 0 s Acinetobacter calcoaceticus var. woffii 0 s Actinobacillus pleuropneumonia 0

More information

Cefuroxime iv Rationale for the EUCAST clinical breakpoints, version th September 2010

Cefuroxime iv Rationale for the EUCAST clinical breakpoints, version th September 2010 Cefuroxime iv Rationale for the EUCAST clinical breakpoints, version 1.0 26 th September 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the

More information

Supplemental Digital Content

Supplemental Digital Content Rapid Diagnosis of Infection in the Critically Ill (RADICAL), a multicenter study of molecular detection in bloodstream infections, pneumonia and sterile site infections Jean-Louis Vincent, David Brealey,

More information

Received 1 March 2011/Returned for modification 19 April 2011/Accepted 20 May 2011

Received 1 March 2011/Returned for modification 19 April 2011/Accepted 20 May 2011 JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 2011, p. 2980 2984 Vol. 49, No. 8 0095-1137/11/$12.00 doi:10.1128/jcm.00431-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Utility of

More information

Consultation on the Revision of Carbapenem Breakpoints

Consultation on the Revision of Carbapenem Breakpoints Consultation on the Revision of Carbapenem Breakpoints July 2018 Please send comments to the EUCAST Scientific Secretary at jturnidge@gmail.com by September 15. EUCAST revision of carbapenem breakpoints

More information

Optimizing MALDI-TOF Use. Clinical Impact Laboratory Impact

Optimizing MALDI-TOF Use. Clinical Impact Laboratory Impact Optimizing MALDI-TOF Use Clinical Impact Laboratory Impact Christine C. Ginocchio, PhD, MT (ASCP) Clinical Professor of Medicine Hofstra North Shore-LIJ School of Medicine, NY VP, Global Microbiology Affairs,

More information

Surveillance of Healthcare Associated Infections in Scottish Intensive Care Units

Surveillance of Healthcare Associated Infections in Scottish Intensive Care Units Surveillance of Healthcare Associated Infections in Scottish Intensive Care Units Annual report of data from January 2010 to December 2010 Scottish Intensive Care Society Audit Group 1 Health Protection

More information

Brief Communication Clinical Microbiology

Brief Communication Clinical Microbiology Brief Communication Clinical Microbiology Ann Lab Med 2017;37:531-535 https://doi.org/10.3343/alm.2017.37.6.531 ISSN 2234-3806 eissn 2234-3814 Comparison of a New Matrix-Assisted Laser Desorption/Ionization

More information

Comparative study of MALDI-TOF MS and VITEK 2 in bacteria identification

Comparative study of MALDI-TOF MS and VITEK 2 in bacteria identification MALDI-TOF MS in Clinical Microbiology Comparative study of MALDI-TOF MS and VITEK 2 in bacteria identification Ling Guo, Liyan Ye, Qiang Zhao, Yanning Ma, Jiyong Yang, Yanping Luo Department of Microbiology,

More information

University of Alberta Hospital Antibiogram for 2007 and 2008 Division of Medical Microbiology Department of Laboratory Medicine and Pathology

University of Alberta Hospital Antibiogram for 2007 and 2008 Division of Medical Microbiology Department of Laboratory Medicine and Pathology University of Alberta Hospital Antibiogram for 2007 and 2008 Division of Medical Microbiology Department of Laboratory Medicine and Pathology This material is supported in part by unrestricted educational

More information

This material is supported in part by unrestricted educational grants from: Abbott, Bayer HealthCare, Merck Frosst, Roche Diagnostics, and Wyeth Inc.

This material is supported in part by unrestricted educational grants from: Abbott, Bayer HealthCare, Merck Frosst, Roche Diagnostics, and Wyeth Inc. Division of Medical Microbiology Department of Laboratory Medicine and Pathology University of Alberta Hospital and Stollery Children's Hospital Antibiogram 2006 This material is supported in part by unrestricted

More information

M O L E C U L A R G E N E T I C S

M O L E C U L A R G E N E T I C S MOLECULAR GENETICS ADVANTAGES OF MOLECULAR GENETICS Molecular genetics is a dynamic and transformative area of diagnostics, leading to insights in research and treatment in many disease states that are

More information

INFECTIOUS DISEASE. Page 2

INFECTIOUS DISEASE. Page 2 Infectious disease Advantages OF TESTING INFECTIOUS DISEASE We are in the middle of a paradigm shift in infectious disease diagnostic testing. As we move from targeted infectious disease testing to a syndromic

More information

DIVISION OF ANTIINFECTIVE DRUG PRODUCTS (HFD-520) CLINICAL MICROBIOLOGY REVIEW NDA Date review completed: 15 Jun 05

DIVISION OF ANTIINFECTIVE DRUG PRODUCTS (HFD-520) CLINICAL MICROBIOLOGY REVIEW NDA Date review completed: 15 Jun 05 Date company submitted: 15 Dec 04 Date received by CDER: 15 Dec 04 Reviewer: Fred Marsik, Ph.D. Date assigned: 15 Dec 04 NAME AND ADDRESS OF APPLICANT Wyeth Pharmaceuticals Inc. P.O. Box 8299 Philadelphia,

More information

ZINEX. Composition Each tablet contains Cefuroxime (as axetil) 250 or 500 mg

ZINEX. Composition Each tablet contains Cefuroxime (as axetil) 250 or 500 mg ZINEX Composition Each tablet contains Cefuroxime (as axetil) 250 or 500 mg Tablets Action Cefuroxime axetil owes its bactericidal activity to the parent compound cefuroxime. Cefuroxime is a well-characterized

More information

Surveillance of Healthcare Associated Infections in Scottish Intensive Care Units

Surveillance of Healthcare Associated Infections in Scottish Intensive Care Units Surveillance of Healthcare Associated Infections in Scottish Intensive Care Units Annual report of data from January 2011 to December 2011 Scottish Intensive Care Society Audit Group Health Protection

More information

Ceftomax TM S (Cefoperazone Sodium plus Sulbactam Sodium Injection)

Ceftomax TM S (Cefoperazone Sodium plus Sulbactam Sodium Injection) COMPOSITION Ceftomax TM S (Cefoperazone Sodium plus Sulbactam Sodium Injection) CEFTOMAX - S Injection 1.5 gm Each vial contains: Cefoperazone Sodium equivalent to Cefoperazone IP. 1,000 mg Sulbactam Sodium

More information

IMIPENEM CILASTATIN SODIUM

IMIPENEM CILASTATIN SODIUM IPC-TEN-IV/IM-082009 PHYSICIANS CIRCULAR IMIPENEM CILASTATIN SODIUM TIENAM Powder for I.V. Infusion Antibacterial IMIPENEM and CILASTATIN SODIUM (TIENAM ) is a broad spectrum beta-lactam antibiotic supplied

More information

Surveillance of Healthcare Associated Infections in Scottish Intensive Care Units

Surveillance of Healthcare Associated Infections in Scottish Intensive Care Units Surveillance of Healthcare Associated Infections in Scottish Intensive Care Units Annual report of data from January - December 2012 Scottish Intensive Care Society Audit Group Health Protection Scotland

More information

INTRA-ABDOMINAL INFECTIONS - II

INTRA-ABDOMINAL INFECTIONS - II William J. Brown, Ph.D. Page 1 of 8 September 21, 2001 (Gastrointestinal Infections VI) INTRA-ABDOMINAL INFECTIONS - II PERITONITIS AND ABSCESSES I. PERITONITIS II. INTRAPERITONEAL ABSCESS III. VISCERAL

More information

VITEK MS Implementation of Mass Spectrometry

VITEK MS Implementation of Mass Spectrometry VITEK MS Implementation of Mass Spectrometry Willson Jang, Technical Leader wljang@providencehealth.bc.ca Microbiology & Virology Laboratory Providence Health Care St. Paul s Hospital October 23, 2013

More information

Primaxin IV Injection

Primaxin IV Injection Seite 1 von 20 Merck Sharp & Dohme Limited Hertford Road, Hoddesdon, Hertfordshire, EN11 9BU Telephone: +44 (0)1992 467 272 Fax: +44 (0)1992 452 206 Medical Information e-mail: medicalinformationuk@merck.com

More information

KENNEL KARE SC DISINFECTANT / CLEANER / DEODORIZER Efficacy Data EPA Reg. #

KENNEL KARE SC DISINFECTANT / CLEANER / DEODORIZER Efficacy Data EPA Reg. # Inc. Efficacy: Disinfection (at ½ ounce per gallon) Kennel Kare SC is bactericidal according to the AOAC Use Dilution Test method on hard inanimate surfaces modified in the presence of 5% organic serum

More information

On-demand diagnosis of TB and rifampinresistance using the Xpert MTB/RIF assay: the present and the future.

On-demand diagnosis of TB and rifampinresistance using the Xpert MTB/RIF assay: the present and the future. On-demand diagnosis of TB and rifampinresistance using the Xpert MTB/RIF assay: the present and the future. David Alland, MD Chief, Division of Infectious Diseases New Jersey Medical School-UMDNJ Newark,

More information

MERREM IV. meropenem PRODUCT INFORMATION COOH CH 3

MERREM IV. meropenem PRODUCT INFORMATION COOH CH 3 MERREM IV meropenem PRODUCT INFORMATION NAME OF THE DRUG Meropenem, as meropenem trihydrate. DESCRIPTION Structural Formula: HO H 3 C O COOH H N S H H H H CH 3 H NH CON(CH 3 ) 2. 3H2 O CAS Number: 119478-56-7

More information

MAGNEX Injection (Sulbactam Sodium/Cefoperazone Sodium 1:1)

MAGNEX Injection (Sulbactam Sodium/Cefoperazone Sodium 1:1) MAGNEX Injection (Sulbactam Sodium/Cefoperazone Sodium 1:1) 1. NAME OF MEDICINAL PRODUCT MAGNEX 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Sulbactam sodium/cefoperazone sodium combination is available

More information

KENNEL KARE SC DISINFECTANT / CLEANER / DEODORIZER Efficacy Data EPA Reg. #

KENNEL KARE SC DISINFECTANT / CLEANER / DEODORIZER Efficacy Data EPA Reg. # Inc. Efficacy: Hospital Disinfection (at ½ ounce per gallon) Kennel Kare SC is bactericidal according to the AOAC Use Dilution Test method on hard inanimate surfaces modified in the presence of 5% organic

More information

SURVEILLANCE BLOODSTREAM INFECTIONS IN BELGIAN HOPITALS ( SEP ) RESULTS ANNUAL REPORT data

SURVEILLANCE BLOODSTREAM INFECTIONS IN BELGIAN HOPITALS ( SEP ) RESULTS ANNUAL REPORT data SURVEILLANCE BLOODSTREAM INFECTIONS IN BELGIAN HOPITALS ( SEP ) RESULTS ANNUAL REPORT data 2000-2014 SEP Workgroup Meeting 24 June 2015 Dr. Naïma Hammami Dr. Marie-Laurence Lambert naima.hammami@wiv-isp.be

More information

BACTERIOLOGY PROGRAMME AND PLAN OF TEACHING 3 rd Semester (academic year )

BACTERIOLOGY PROGRAMME AND PLAN OF TEACHING 3 rd Semester (academic year ) BACTERIOLOGY PROGRAMME AND PLAN OF TEACHING 3 rd Semester (academic year 2012-2013) 19. 10. 2012. Introduction in microbiology, bacterial taxonomy, general bacterial prop Bacterial structures, biosynthesis

More information

Cell counting (EtBr) Before cell-lysis. Cell-lysis by 3% SDS beads beating. After cell-lysis

Cell counting (EtBr) Before cell-lysis. Cell-lysis by 3% SDS beads beating. After cell-lysis Key words Sample Cell counting (EtBr) DNA extraction Cell-lysis by 3% SDS beads beating Before cell-lysis After cell-lysis Cell-lysis efficiency (Maintained70%) PCR PCR amplification of partial fragments

More information

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory CEFTUM TABLETS. Cefuroxime Axetil Tablets IP 125/250/500mg

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory CEFTUM TABLETS. Cefuroxime Axetil Tablets IP 125/250/500mg For the use only of Registered Medical Practitioners or a Hospital or a Laboratory CEFTUM TABLETS Cefuroxime Axetil Tablets IP 125/250/500mg QUALITATIVE AND QUANTITATIVE COMPOSITION CEFTUM TABLETS 125

More information

HYPOCHLOROUS ACID (HOCl) Our Body's immune system protector in a BOTTLE

HYPOCHLOROUS ACID (HOCl) Our Body's immune system protector in a BOTTLE AQUAOX IS A REVOLUTIONARY DISINFECTION SOLUTION WHICH ACTIVE INGREDIENT HOCL IS NON HAZARDOUS, HAS NO FRAGRANCE, AND IS SAFE ON ALL SURFACES (AND ON SKIN.) HYPOCHLOROUS ACID (HOCl) Our Body's immune system

More information

Vancomycin Rationale for the EUCAST clinical breakpoints, version June 2010

Vancomycin Rationale for the EUCAST clinical breakpoints, version June 2010 Vancomycin Rationale for the EUCAST clinical breakpoints, version 2.1 17 June 2010 Introduction The glycopeptides are a class of agents composed of amino acid residues and attached sugars. Glycopeptides

More information

MINISTRY OF HEALTH OF THE REPUBLIC OF BELARUS. Patient Information Leaflet

MINISTRY OF HEALTH OF THE REPUBLIC OF BELARUS. Patient Information Leaflet No. 851 of August 19, 2014 КЛС No. 10 of July 31, 2014 Invented trade name: Cefosulbactam MINISTRY OF HEALTH OF THE REPUBLIC OF BELARUS Patient Information Leaflet CEFOSULBACTAM (ЦЕФОСУЛЬБАКТАМ) Powder

More information

Efficacy Data. Disinfectant Cleaner & Odor Counteractant EPA REG. #

Efficacy Data. Disinfectant Cleaner & Odor Counteractant EPA REG. # SENTS-ALE Hospital Disinfection (at 2 ounces per gallon)) Scents-Able is bactericidal according to the AOA Use Dilution Test method on hard inanimate surfaces modified in the presence of 5% organic serum

More information

Q 1 (May-July 2016) Q 2 (August-October 2016) Q 3 (November 2016-January 2017)

Q 1 (May-July 2016) Q 2 (August-October 2016) Q 3 (November 2016-January 2017) Adult ICU: May 2016-July 2017 Table 1a. Counts and rates of positive blood cultures and blood stream infections which meet the case definition in your critical care unit and for all adult critical care

More information

Potential Reimbursement CPT Codes

Potential Reimbursement CPT Codes BioFire FilmArray Blood Culture Identification (BCID) Panel Medicare All targets (n) 87150 n x * *BioFire BCID Panel is comprised of 27 total targets. The number of targets allowed for reimbursement may

More information

S. Q. van Veen,* E. C. J. Claas, and Ed J. Kuijper. Department of Medical Microbiology, Leiden University Medical Center, Leiden, Netherlands

S. Q. van Veen,* E. C. J. Claas, and Ed J. Kuijper. Department of Medical Microbiology, Leiden University Medical Center, Leiden, Netherlands JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 2010, p. 900 907 Vol. 48, No. 3 0095-1137/10/$12.00 doi:10.1128/jcm.02071-09 Copyright 2010, American Society for Microbiology. All Rights Reserved. High-Throughput

More information

FAROBACT 200 Tablets (Faropenem)

FAROBACT 200 Tablets (Faropenem) Published on: 10 Jul 2014 FAROBACT Tablets (Faropenem) Composition FAROBACT Tablets Each film-coated tablet contains: Faropenem Sodium equivalent to Faropenem... Dosage Form Oral tablet Pharmacology Pharmacodynamics

More information

Monitoring of Enhanced Surveillance for Severe and Fatal Pneumonia, 1 April - 30 June 2014

Monitoring of Enhanced Surveillance for Severe and Fatal Pneumonia, 1 April - 30 June 2014 Monitoring of Enhanced Surveillance for Severe and Fatal Pneumonia, 1 April - 3 June 214 1. The cumulative cases report since December 21 and cases report during April to June 214 During 1 April to 3 June

More information

Tigecycline activity tested against 26, 474 bloodstream infection isolates: a collection from 6 continents

Tigecycline activity tested against 26, 474 bloodstream infection isolates: a collection from 6 continents Diagnostic Microbiology and Infectious Disease 52 (2005) 181 186 www.elsevier.com/locate/diagmicrobio Tigecycline activity tested against 26, 474 bloodstream infection isolates: a collection from 6 continents

More information

Objective: To assess the incidence of healthcare-associated infections (HAI) and the prevalence

Objective: To assess the incidence of healthcare-associated infections (HAI) and the prevalence Abstract Objective: To assess the incidence of healthcare-associated infections (HAI) and the prevalence of pathogens across all pediatric units within a single hospital, and trends in pediatric HAI over

More information

Quality Control Strains

Quality Control Strains Quality Control Strains Commercial firms specify ATCC strains as controls for rapid identification, minimum inhibitory concentration of antibiotics and antibiotic susceptibility panels. Species and strains

More information

Monitoring of Enhanced Surveillance for Severe and Fatal Pneumonia, 1 st January 31 st March 2015

Monitoring of Enhanced Surveillance for Severe and Fatal Pneumonia, 1 st January 31 st March 2015 Monitoring of Enhanced Surveillance for Severe and Fatal Pneumonia, 1 st January 31 st March 2015 1. The cumulative cases report since December 2010 and cases report during January to March 2015 During

More information

Normal Human Flora. (Human Microbiome) Dr.Sarmad M.H. Zeiny Baghdad College of Medicine

Normal Human Flora. (Human Microbiome) Dr.Sarmad M.H. Zeiny Baghdad College of Medicine Normal Human Flora (Human Microbiome) Dr.Sarmad M.H. Zeiny Baghdad College of Medicine 2014-2015 Objectives Describe important human normal flora. Demonstrate the epidemiology of human normal flora. Determine

More information

PHYSICIANS CIRCULAR. Tablets NOROXIN (norfloxacin, USP)

PHYSICIANS CIRCULAR. Tablets NOROXIN (norfloxacin, USP) PHYSICIANS CIRCULAR Tablets NOROXIN is a quinolone carboxylic acid antibacterial agent for oral administration. MICROBIOLOGY NOROXIN has a broad spectrum of antibacterial activity against gram-positive

More information

Antimicrobial Activity and Spectrum of PPI-0903M (T-91825), a Novel Cephalosporin, Tested against a Worldwide Collection of Clinical Strains

Antimicrobial Activity and Spectrum of PPI-0903M (T-91825), a Novel Cephalosporin, Tested against a Worldwide Collection of Clinical Strains ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2005, p. 3501 3512 Vol. 49, No. 8 0066-4804/05/$08.00 0 doi:10.1128/aac.49.8.3501 3512.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.

More information

Physical Properties Appearance: Clear Liquid Fragrance: Fragrance Free Form: Gel ph: INCI Name*

Physical Properties Appearance: Clear Liquid Fragrance: Fragrance Free Form: Gel ph: INCI Name* TECHNICAL BULLETIN PURELL Advanced Hygienic Hand Rub Technical Data INDICATIONS: Hygienic hand rub to help reduce bacteria on the skin that may be harmful METHOD OF USE: For Hygienic Hand Rub: Apply approximately

More information

ZOSUL Injection (Cefoperazone Sodium + Sulbactam Sodium) Cefoperazone Sodium Plus Sulbactam Sodium Injection Zosul

ZOSUL Injection (Cefoperazone Sodium + Sulbactam Sodium) Cefoperazone Sodium Plus Sulbactam Sodium Injection Zosul Published on: 10 Jul 2014 ZOSUL Injection (Cefoperazone Sodium + Sulbactam Sodium) Cefoperazone Sodium Plus Sulbactam Sodium Injection Zosul Composition ZOSUL Injection 1.0 g Each vial contains: Cefoperazone

More information

Surveillance for Central Line Associated Blood Stream Infections (CLABSI) in Intensive Care Units

Surveillance for Central Line Associated Blood Stream Infections (CLABSI) in Intensive Care Units Canadian Nosocomial Infection Surveillance Program Surveillance for Central Line Associated Blood Stream Infections (CLABSI) in Intensive Care Units 2017 CLABSI Surveillance Protocol Revised November 7

More information

PRODUCT INFORMATION. Meropenem Kabi powder for intravenous injection or infusion 500 mg 1 g

PRODUCT INFORMATION. Meropenem Kabi powder for intravenous injection or infusion 500 mg 1 g Meropenem Kabi Powder for Injection NAME OF THE MEDICINE Meropenem, as meropenem trihydrate. PRODUCT INFORMATION The chemical name of meropenem trihydrate is Azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid,

More information

KOMAR UNIVERSITY OF SCIENCE AND TECHNOLOGY (KUST) Medical Bacteriology Syllabus (Theory) Spring 2016

KOMAR UNIVERSITY OF SCIENCE AND TECHNOLOGY (KUST) Medical Bacteriology Syllabus (Theory) Spring 2016 Course Title Medical Bacteriology Syllabus (Theory) Spring 2016 Medical Bacteriology Course Code MLS3330 No. of Credits Department Medical Laboratory Science (MLS) College Science Pre-requisites Course

More information

Healthcare-associated infections acquired in intensive care units

Healthcare-associated infections acquired in intensive care units SURVEILLANCE REPORT Annual Epidemiological Report for 2015 Healthcare-associated infections acquired in intensive care units Key facts In 2015, 11 788 (8.3%) of patients staying in an intensive care unit

More information

DISEASE OUTBREAKS SUMMARY

DISEASE OUTBREAKS SUMMARY DISEASE OUTBREAKS SUMMARY Outbreaks may be defined as (a) clusters of cases related in time and place or (b) occurrence of disease above a baseline or threshold level in a defined location. In Los Angeles

More information

Streptococci facultative anaerobe

Streptococci facultative anaerobe THE GENUS STREPTOCOCCUS The genus Streptococcus obtains Gram-positive cocci, nonmotile, nonsporeforming, arranged mostly in chains or in pairs. Most species are facultative anaerobes. Some of streptococci

More information

PATHOGEN DETECTION WITH THE FILMARRAY

PATHOGEN DETECTION WITH THE FILMARRAY PATHOGEN DETECTION WITH THE FILMARRAY The System Sample-to-Answer in an Hour Single sample Multiple samples The FilmArray integrates sample preparation, amplification, detection, and analysis all into

More information

For use with Sofia only

For use with Sofia only For use with Sofia only INTENDED USE The Sofia S. pneumoniae FIA employs immunofluorescence for qualitative detection of Streptococcus pneumoniae antigen in urine specimens of patients with pneumonia and

More information

Cefuroxime (as sodium)

Cefuroxime (as sodium) Cefuroxime (as sodium) Zinacef Powder for Injection Antibacterial PRODUCT DESCRIPTION Cefuroxime (as sodium) (Zinacef ) 250mg Powder for Injection: Each white to faintly yellow powder to which appropriate

More information

THE KENYA POLYTECHNIC UNIVERSITY COLLEGE

THE KENYA POLYTECHNIC UNIVERSITY COLLEGE THE KENYA POLYTECHNIC UNIVERSITY COLLEGE SCHOOL OF HEALTH SCIENCES AND TECHNOLOGY DEPARTMENT OF BIOMEDICAL LABORATORY SCIENCES AND TECHNOLOGY DIPLOMA IN MEDICAL LABORATORY SCIENCES FINAL YEAR EXAMINATION

More information

Clinical and Microbiological Evaluation of Osteomyelitis

Clinical and Microbiological Evaluation of Osteomyelitis Bahrain Medical Bulletin, Vol.23, No.2, June 2001 Clinical and Microbiological Evaluation of Osteomyelitis Haider Abdul-Lateef Mousa, MBChB, MSc* Thamer A Hamdan, MBChB, FRCS** Sundus S Bakr, BSc, PhD***

More information

Microbial Environment of Spacecraft

Microbial Environment of Spacecraft Microbial Environment of Spacecraft Duane L. Pierson, Ph.D. NASA Johnson Space Center April 2007 Microbiology Lab Johnson Space Center-NASA 2 ADVERSE EFFECTS OF MICROORGANISMS Infectious Diseases Toxin

More information

Yes No Unknown. In hospital Out of hospital Unknown. Blood Pump Drive Unit Failure External Control System Failure. Yes No Unknown

Yes No Unknown. In hospital Out of hospital Unknown. Blood Pump Drive Unit Failure External Control System Failure. Yes No Unknown Adverse Events Device Malfunction Was there a device malfunction: Date of event: Was there a device malfunction: Major pump unit involved: Check all the apply Suspected device Thrombosis: Anticoagulant

More information

CERTIFICATION. Certificate No. The AOAC Research Institute hereby certifies that the performance of the test kit known as: Compact Dry EC

CERTIFICATION. Certificate No. The AOAC Research Institute hereby certifies that the performance of the test kit known as: Compact Dry EC CERTIFICATION AOAC Performance Tested SM Certificate No. 110402 The AOAC Research Institute hereby certifies that the performance of the test kit known as: Compact Dry EC manufactured by NISSUI Pharmaceutical

More information

Patient: Ima Sample. Accession: Shiloh Rd, Ste 101. Collected: 9/4/2018. Received: 9/6/2018 Alpharetta GA

Patient: Ima Sample. Accession: Shiloh Rd, Ste 101. Collected: 9/4/2018. Received: 9/6/2018 Alpharetta GA GI-MAP TM DNA Stool Analysis Patient: Ima Sample Accession: 20180906-0001 5895 Shiloh Rd, Ste 101 Collected: 9/4/2018 Received: 9/6/2018 Alpharetta GA 30005 877-485-5336 DOB: 9/1/2009 Completed: 9/6/2018

More information

Patient: Ima Sample. Accession: Shiloh Rd, Ste 101. Collected: 2/10/2018. Received: 2/12/2018 Alpharetta GA

Patient: Ima Sample. Accession: Shiloh Rd, Ste 101. Collected: 2/10/2018. Received: 2/12/2018 Alpharetta GA GI-MAP TM DNA Stool Analysis Patient: Ima Sample Accession: 20180212-0001 5895 Shiloh Rd, Ste 101 Collected: 2/10/2018 Received: 2/12/2018 Alpharetta GA 30005 877-485-5336 DOB: 7/11/1981 Completed: Ordered

More information

DORIBAX for injection

DORIBAX for injection DORIBAX for injection 500 mg Powder for Intravenous Infusion NAME OF THE MEDICINE Doripenem (as monohydrate) PRODUCT INFORMATION The chemical name for doripenem monohydrate is (4R,5S,6S)-3-[((3S,5S)-5-

More information

Infection Control in Collegiate Wrestling Part I

Infection Control in Collegiate Wrestling Part I Infection Control in Collegiate Wrestling Part I This presentation was developed with a grant from the NCAA by: Mary Ann Custer Mary Ann Custer Custermac@aol.com 1 2 Ringworm Impetigo SOUND FAMILIAR? Herpes

More information

CEFOBID (sterile cefoperazone, USP) Formerly known as sterile cefoperazone sodium, USP

CEFOBID (sterile cefoperazone, USP) Formerly known as sterile cefoperazone sodium, USP CEFOBID (sterile cefoperazone, USP) Formerly known as sterile cefoperazone sodium, USP PHARMACY BULK PACKAGE NOT FOR DIRECT INFUSION DESCRIPTION CEFOBID (cefoperazone), formerly known as cefoperazone sodium,

More information

IMMUVIEW S. PNEUMONIAE ANTIGEN TEST. Lateral flow test for qualitative detection of S. pneumoniae in urine and cerebrospinal fluid.

IMMUVIEW S. PNEUMONIAE ANTIGEN TEST. Lateral flow test for qualitative detection of S. pneumoniae in urine and cerebrospinal fluid. IMMUVIEW S. PNEUMONIAE ANTIGEN TEST Lateral flow test for qualitative detection of S. pneumoniae in urine and cerebrospinal fluid. 2 IMMUVIEW S. PNEUMONIAE ANTIGEN TEST For in vitro diagnostic use Application

More information

Syndromic Testing: The right test, the first time.

Syndromic Testing: The right test, the first time. Syndromic Testing: The right test, the first time. Don t guess. Know. Infectious disease diagnostics has evolved. BioFire s syndromic approach is making the world a healthier place. Many infectious diseases

More information

VOLOXAL. Composition each tablet contains levofloxacin 500 & 750 mg

VOLOXAL. Composition each tablet contains levofloxacin 500 & 750 mg VOLOXAL Composition each tablet contains levofloxacin 500 & 750 mg Tablets Action Bactericidal; as a fluoroquinolone antibacterial agent, levofloxacin acts on the DNA-gyrase complex and topoisomerase IV

More information

Comparison of CPS ID 3 and CHROMagar Orientation chromogenic agars with standard biplate technique for culture of clinical urine samples

Comparison of CPS ID 3 and CHROMagar Orientation chromogenic agars with standard biplate technique for culture of clinical urine samples J Microbiol Immunol Infect. 2008;41:422-427 Comparison of CPS ID 3 and CHROMagar Orientation chromogenic agars with standard biplate technique for culture of clinical urine samples Jen-Chyi Chang 1,2,

More information

National Surveillance of Infections acquired in Intensive Care Units

National Surveillance of Infections acquired in Intensive Care Units National Surveillance of Infections acquired in Intensive Care Units Annual Report 2015 Public Health & Surveillance Healthcare-associated infections and Antimicrobial resistance Juliette Wytsmanstraat

More information

Cefuroxime sodium equivalent to Cefuroxime 250 mg, 750 mg and 1.5 g Powder for Injection

Cefuroxime sodium equivalent to Cefuroxime 250 mg, 750 mg and 1.5 g Powder for Injection Cefuroxime-AFT Cefuroxime sodium equivalent to Cefuroxime 250 mg, 750 mg and 1.5 g Powder for Injection Presentation CEFUROXIME-AFT 250 mg contains Cefuroxime sodium equivalent to Cefuroxime 250 mg. CEFUROXIME-AFT

More information

1430 West McCoy Lane Santa Maria, CA p:

1430 West McCoy Lane Santa Maria, CA p: 091217TR HardyCHROM BluEcoli 1 HardyCHROM Candida 2 HardyCHROM ECC 3 HardyCHROM ESBL 4 HardyCHROM Listeria 5 HardyCHROM MRSA 6 HardyCHROM O157 7 HardyCHROM Salmonella 8 HardyCHROM SS NoPRO 9 HardyCHROM

More information

Summary of Product Characteristics

Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Summary of Product Characteristics Meronem I.V. 1g Powder for solution for injection or infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains meropenem

More information

Original Article Clinical Microbiology INTRODUCTION

Original Article Clinical Microbiology INTRODUCTION Original Article Clinical Microbiology Ann Lab Med 2015;35:416-422 http://dx.doi.org/10.3343/alm.2015.35.4.416 ISSN 2234-3806 eissn 2234-3814 Direct Identification of Urinary Tract Pathogens From Urine

More information

Bacterial composition in the supragingival plaques of children with and without dental caries

Bacterial composition in the supragingival plaques of children with and without dental caries 182 Ro kiewicz D, et al. Advances in Medical Sciences Vol. 51 2006 Suppl. 1 Bacterial composition in the supragingival plaques of children with and without dental caries Ro kiewicz D 1, Daniluk T 2, Zaremba

More information

Bacterial Interference by Streptococcus salivarius

Bacterial Interference by Streptococcus salivarius Bacterial Interference by Streptococcus salivarius NANCY J. BILL, B.S.M.T. (ASCP), AND JOHN A. WASHINGTON II, M.D. Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55901 ABSTRACT Bill, Nancy J. and

More information

Recommendations for Dilution Susceptibility Testing Concentrations of the Cefoperazone-Sulbactam Combination

Recommendations for Dilution Susceptibility Testing Concentrations of the Cefoperazone-Sulbactam Combination JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 1987. p. 1725-1729 0095-1137/87/091725-05$02.00/O Copyright (O 1987, American Society for Microbiology Vol. 25, No. 9 In Vitro Antimicrobial Spectrum, Occurrence

More information

Infection Data: Form Updates

Infection Data: Form Updates Infection Data: Form Updates Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC Overview Why is infection data important?

More information

Bio Microbiology - Spring 2013 Study Guide 20 Normal Flora - Normal Responses - Disease

Bio Microbiology - Spring 2013 Study Guide 20 Normal Flora - Normal Responses - Disease Bio 230 - Microbiology - Spring 2013 Study Guide 20 Normal Flora - Normal Responses - Disease It has been calculated that the normal human houses about 10 12 bacteria on the skin, 10 10 in the mouth, and

More information

MALDI-TOF mass spectrometry for direct bacterial identification

MALDI-TOF mass spectrometry for direct bacterial identification JCM Accepts, published online ahead of print on 17 February 2010 J. Clin. Microbiol. doi:10.1128/jcm.01780-09 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All

More information

Utility of Gram stain in the clinical management of suspected ventilator-associated pneumonia Secondary analysis of a multicenter randomized trial

Utility of Gram stain in the clinical management of suspected ventilator-associated pneumonia Secondary analysis of a multicenter randomized trial Journal of Critical Care (2008) 23, 74 81 Utility of Gram stain in the clinical management of suspected ventilator-associated pneumonia Secondary analysis of a multicenter randomized trial M. Albert MD

More information

Class 15. Infections of the Central Nervous System

Class 15. Infections of the Central Nervous System English Division 6 E.D. Class 15 Infections of the Central Nervous System Pathogenesis, etiologic agents, clinical symptoms, and laboratory diagnosis To be performed: - Read carefully attached case studies

More information

Summary of Product Characteristics

Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Meroponia 1g Powder for Solution for Injection or Infusion Summary of Product Characteristics 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains meropenem trihydrate

More information

COONa CH 2 OCOCH 3 CONH H

COONa CH 2 OCOCH 3 CONH H Y36-002-528 DUPLEX Package Insert DRUG DELIVERY SYSTEM CefOTAXime for Injection USP and Dextrose Injection To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefotaxime

More information

605 Springs Road Bedford, MA

605 Springs Road Bedford, MA EFFICACY DATA FOR BIO-CLEAN (EPA Reg. No. ) VIRUCIDAL DATA: Test Methods: *U.S E.P.A Pesticide Assessment Guidelines, Subdivision G: Product Performance, Section 91-2(f), and Section 91-30 (d),(e), November,

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Doribax 250 mg powder for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains doripenem monohydrate

More information

CEFPROZIL FOR ORAL SUSPENSION USP 125 mg/5 ml and 250 mg/5 ml. Rx Only

CEFPROZIL FOR ORAL SUSPENSION USP 125 mg/5 ml and 250 mg/5 ml. Rx Only CEFPROZIL FOR ORAL SUSPENSION USP 125 mg/5 ml and 250 mg/5 ml Rx Only To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil for oral suspension and other antibacterial

More information

Clinical Implications of Positive Blood Cultures

Clinical Implications of Positive Blood Cultures CLINICAL MICROBIOLOGY REVIEWS, Oct. 1989, p. 329-353 Vol. 2, No. 4 0893-8512/89/040329-25$02.00/0 Copyright 1989, American Society for Microbiology Clinical Implications of Positive Blood Cultures CHARLES

More information

M E D I C A L L A B O R A T O R Y

M E D I C A L L A B O R A T O R Y M E D I C A L L A B O R A T O R Y E V A L U A T I O N PARTICIPANT SUMMARY 2 0 1 8 Microbiology 2018 MLE-M1 Total Commitment to Education and Service Provided by ACP, Inc. Evaluation Criteria... 2 Microbiology

More information

CEFPROZIL FOR ORAL SUSPENSION USP 125 mg/5 ml and 250 mg/5 ml. Rx only

CEFPROZIL FOR ORAL SUSPENSION USP 125 mg/5 ml and 250 mg/5 ml. Rx only CEFPROZIL FOR ORAL SUSPENSION USP 125 mg/5 ml and 250 mg/5 ml Rx only To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil for oral suspension and other antibacterial

More information

Anaerobes Bacteroides species, Clostridium species (Note: most strains of C.difficile are resistant).

Anaerobes Bacteroides species, Clostridium species (Note: most strains of C.difficile are resistant). CEFIXON Composition Each vial contains 1 g Ceftriaxone (as sodium). Vial Action The bactericidal activity of Ceftriaxone results from inhibition of cell wall Synthesis. Ceftriaxone has a high degree of

More information

Cefuroxime (as sodium)

Cefuroxime (as sodium) Cefuroxime (as sodium) Zinacef Powder for Injection Antibacterial PRODUCT DESCRIPTION Cefuroxime (as sodium) (Zinacef ) 250mg Powder for Injection: Each white to faintly yellow powder to which appropriate

More information